Company news
Harrow, Inc. news in 2023
Harrow, Inc.'s news releases, calls and decks from 2023, newest first.
Harrow Completes Transfer of the TRIESENCE® New Drug Application
November 28, 2023
Harrow to Present at Two Investor Conferences in November
November 19, 2023
Harrow Announces Third Quarter 2023 Financial Results
November 12, 2023
Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023
October 29, 2023
Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S.
October 23, 2023
Harrow Health, Inc. Changes Corporate Name to Harrow, Inc.
September 28, 2023
Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation
September 25, 2023
Harrow Announces Second Quarter 2023 Financial Results
August 8, 2023
Harrow Launches VIGAMOX® in the U.S.
July 30, 2023
Harrow to Announce Second Quarter 2023 Financial Results on August 9, 2023
July 25, 2023
Harrow Prices $60 Million Public Offering of Common Stock
July 18, 2023
Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance
July 17, 2023
Harrow Announces Proposed Public Offering of Common Stock
July 17, 2023
Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq
July 17, 2023
Harrow Acquires Santen’s Branded Ophthalmic Portfolio
July 17, 2023
Harrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023
May 16, 2023
Harrow Announces First Quarter 2023 Financial Results
May 10, 2023
Harrow to Launch FDA-Approved IHEEZO™ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
May 3, 2023
Harrow Launches ILEVRO®, NEVANAC®, and MAXIDEX® in the U.S.
May 1, 2023
Harrow to Announce First Quarter 2023 Financial Results on May 11, 2023
April 26, 2023
Harrow Announces New $100 Million Secured Credit Facility with Oaktree
March 27, 2023
Harrow Announces Fourth Quarter and Year-End 2022 Financial Results
March 22, 2023
Harrow Announces Transitional Pass-Through Reimbursement Status for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3%
March 12, 2023
Harrow Announces Appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance
March 5, 2023
Harrow to Announce Fourth Quarter 2022 Financial Results on March 23, 2023
March 1, 2023
Harrow Launches Next-Generation Compounded Atropine Formulations
February 14, 2023
Harrow Announces Permanent, Product-Specific J-Code (J2403) for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia Effective April 1, 2023
February 1, 2023
Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Will Begin Receiving Net Profit Payments for Acquired Products
January 22, 2023
Harrow Announces Availability of Fortisite™ Formulations for In-Office Use
January 4, 2023
Calls in 2023
Decks in 2023
- Harrow Health — Investor Presentation (July 2023)
Investor deck · 16 slides · Jul 18, 2023
- Harrow Health — Investor Presentation (May 2023)
Investor deck · 16 slides · May 11, 2023